This paper examines whether treatment of pulmonary alveolar proteinosis (PAP) is shifting from the established physical intervention of whole lung lavage (WLL) toward emerging pharmacological therapies.
The review suggests a trend toward pharmacological approaches (such as GM-CSF supplementation and other targeted agents) as alternatives or adjuncts to WLL, though no definitive head-to-head outcome data are cited to firmly establish superiority of one approach.
As an editorial or review-type article, it lacks primary outcome data from controlled trials; conclusions are based on existing literature rather than new empirical evidence.
Clinicians managing PAP should be aware of evolving pharmacological options (e.g., inhaled or subcutaneous GM-CSF) that may reduce reliance on repeated whole lung lavage, but WLL remains a cornerstone treatment until more robust trial data support a definitive shift.
Explore related topics
